Apomorphine may still outpace ropinirole for canine emesis

The debate over apomorphine versus ropinirole as a canine emetic is shifting from theory to evidence. Recent comparative studies suggest that while ropinirole eye drops remain an effective and FDA-approved option, IV apomorphine may still be the stronger choice when speed and first-dose reliability matter most in acute toxin or foreign-body cases. (pubmed.ncbi.nlm.nih.gov)

That question has become more relevant since the FDA approved Clevor, a ropinirole ophthalmic solution, in June 2020 as the first approved veterinary drug in the U.S. specifically indicated to induce vomiting in dogs. Before that, many clinicians relied on apomorphine, a dopamine agonist long used extra-label for emesis induction in dogs by IV, subconjunctival, SC, IM, or oral routes. Illinois veterinary pharmacy guidance notes that both agents can be appropriate, but they differ in approval status, administration, onset, and adverse-effect profile. (fda.gov)

The newer data are mixed, depending on setting and study design. In a 2023 JAVMA clinical trial involving 279 client-owned dogs with known or suspected toxin or foreign-material ingestion, ropinirole produced emesis in 91.4% overall, with 78.9% responding to a single dose and an average time to emesis of 11 minutes. Investigators concluded it was safe and effective, though still slightly less effective than apomorphine based on historical comparison. (pubmed.ncbi.nlm.nih.gov)

A 2024 emergency department study, however, drew a sharper distinction. In that head-to-head comparison, ropinirole had an 81% first-dose success rate versus 99% for apomorphine, a much longer median time to first emetic event, and a substantially higher need for antiemetic rescue, 37% versus 0%. The prospective randomized trial enrolled 132 client-owned dogs from two specialty referral hospitals between October 2021 and March 2023 after suspected or confirmed toxin or foreign-body ingestion. Dogs were randomized to ropinirole eye drops or IV apomorphine, and if vomiting did not occur within 20 minutes, a second identical dose was given with monitoring continued for 40 minutes. Exclusion criteria included dogs younger than 4.5 months, under 1.8 kg, with ocular disease, CNS or hepatic disease, prior antiemetic treatment, or ingestion of materials for which emesis was contraindicated, such as caustics or volatile substances. The authors concluded apomorphine was clinically superior for dogs presenting to the ER when rapid decontamination was needed. (pubmed.ncbi.nlm.nih.gov)

Then, in a 2025 blinded randomized crossover trial in 24 healthy dogs, investigators reported no significant difference in overall efficacy between the drugs, with median onset still much faster for apomorphine, 1.18 minutes versus 8.85 minutes for ropinirole. Adverse effects were broadly similar, but ocular redness and protracted vomiting were more common with ropinirole. That helps explain why the literature can sound conflicting: overall success may converge in controlled settings, while emergency clinicians may care more about immediate response and the need for follow-up intervention. (frontiersin.org)

Industry and clinical guidance add another layer. According to the FDA label and product information, dogs treated with Clevor can receive a second dose if they do not vomit within 20 minutes, and treatment success in the approval study was defined as vomiting within 30 minutes; 95% of treated dogs vomited within that window. University of Illinois guidance also emphasizes that ropinirole is approved only for dogs at least 4.5 months old and 1.8 kg or larger, while apomorphine remains an extra-label tool without the same labeled age restriction. In practice, rescue antiemetics are part of these protocols too: the ER comparison described maropitant use after apomorphine and metoclopramide use after ropinirole, and the antiemetic landscape may broaden further with Dechra’s newly approved Emeprev, an injectable maropitant bioequivalent the company says will launch in early 2026. Dechra says the product does not require refrigeration and includes benzyl alcohol, which has been associated with less injection discomfort in dogs. (vetoquinolusa.com)

Why it matters: For veterinary professionals, this is less about declaring a universal winner than matching the drug to the case. In a stable dog where an on-label, needle-free option is attractive, ropinirole may fit well. In a time-sensitive emergency, especially when every minute matters for toxin exposure, the faster onset and higher first-dose success reported with apomorphine could influence protocol choices. Either way, emesis still has to be used selectively. Clinical guidance warns against inducing vomiting after ingestion of caustics, hydrocarbons, or sharp objects, in patients unable to protect their airway, or when significant time has elapsed and the risk-benefit balance has changed. (vetmed.illinois.edu)

What to watch: The next step is whether emergency and primary care practices formalize different emesis pathways based on urgency, route preference, and expected need for reversal or rescue therapy, and whether future comparative trials in real-world poisoned dogs narrow the gap between label convenience and clinical performance. The arrival of additional maropitant injectables could also matter at the workflow level if clinics are looking for easier storage and less painful rescue-treatment options. (pubmed.ncbi.nlm.nih.gov)